We have shown that the dual activation of the PI3K and Ras/MAPK pathways, via PTEN loss and KRAS activation, is sufficient to promote robust tumor growth and thus, have developed a novel model system for elucidation of potential crosstalk and novel feedback mechanisms. The gene discussed is KRAS; the disease is neoplasm.